Home/Pipeline/PCSK9 inhibitor

PCSK9 inhibitor

Hypercholesterolemia (statin‑resistant)

PreclinicalActive

Key Facts

Indication
Hypercholesterolemia (statin‑resistant)
Phase
Preclinical
Status
Active
Company

About Nyrada

Australian‑listed biotech advancing TRPC‑channel inhibitors for cardiovascular and neurological unmet needs.

View full company profile